First‐in‐human safety, tolerability, and pharmacokinetic results of DFV890, an oral low‐molecular‐weight NLRP3 inhibitor

• Main Authors: Ewa Gatlik (Author), Beata Mehes (Author), Emilie Voltz (Author), Ulrike Sommer (Author), Elaine Tritto (Author), Giulia Lestini (Author), Xiaoxi Liu (Author), Parasar Pal (Author), Maria Velinova (Author), Wiliam S. Denney (Author), Yunlin Fu (Author), Anthony Opipari (Author), Dennis Dean (Author), Guido Junge (Author)
• Format: Book
• Published: Wiley, 2024-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract This first‐in‐human study evaluated the safety, tolerability, single‐ and multiple‐dose pharmacokinetic profiles with dietary influence, and pharmacodynamics (PD) of DFV890, an oral NLRP3 inhibitor, in healthy participants. In total, 122 participants were enrolled into a three‐part trial in...